4D Molecular Therapeutics (NASDAQ:FDMT) Releases Quarterly Earnings Results, Beats Estimates By $0.96 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) announced its quarterly earnings results on Wednesday. The company reported $0.43 EPS for the quarter, beating the consensus estimate of ($0.53) by $0.96, FiscalAI reports. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The company had revenue of $85.09 million for the quarter, compared to analyst estimates of $30.86 million.

4D Molecular Therapeutics Trading Down 0.6%

FDMT stock traded down $0.05 during mid-day trading on Wednesday, hitting $8.56. The stock had a trading volume of 533,104 shares, compared to its average volume of 734,697. The stock has a market capitalization of $489.08 million, a price-to-earnings ratio of -2.28 and a beta of 2.99. The company has a fifty day moving average of $8.68 and a 200 day moving average of $9.09. 4D Molecular Therapeutics has a 1-year low of $2.23 and a 1-year high of $12.34.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. increased its holdings in shares of 4D Molecular Therapeutics by 23.9% during the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after acquiring an additional 1,090,000 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in 4D Molecular Therapeutics by 164.4% in the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock worth $34,726,000 after purchasing an additional 2,882,508 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in 4D Molecular Therapeutics by 4.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock worth $32,272,000 after purchasing an additional 174,489 shares during the period. State Street Corp grew its holdings in 4D Molecular Therapeutics by 197.5% during the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after purchasing an additional 1,785,106 shares during the last quarter. Finally, Federated Hermes Inc. grew its holdings in 4D Molecular Therapeutics by 33.4% during the second quarter. Federated Hermes Inc. now owns 1,667,338 shares of the company’s stock valued at $6,186,000 after purchasing an additional 417,157 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

Analysts Set New Price Targets

FDMT has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Barclays assumed coverage on 4D Molecular Therapeutics in a report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 target price on the stock. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 7th. Chardan Capital reiterated a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, December 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $31.67.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.